Powered by MOMENTUM MEDIA
Powered by MOMENTUM MEDIA

Website Notifications

Get notifications in real-time for staying up to date with content that matters to you.

JP2060 Phase 3 contender sets sights on human health research

monash leidos mou

Leidos Australia has signed a memorandum of understanding (MoU) with Monash University to collaborate on research and development at the Monash Institute of Medical Engineering (MIME).

Leidos Australia has signed a memorandum of understanding (MoU) with Monash University to collaborate on research and development at the Monash Institute of Medical Engineering (MIME).

MIME fosters and co-ordinates translational medtech research across Monash University faculties, partner hospitals and collaborating medical research institutions. The clinician-led research programs focus on major clinical and health system needs, and integrate expertise from across engineering, information technology, science, biomedical and clinical research to develop new devices, diagnostics, therapeutics, delivery systems and clinical tools.

Advertisement
Advertisement

The MoU, signed by the director of MIME, Professor Jeffrey Rosenfeld AM, OBE, and Leidos Australia technical director Dan Brewer, will focus on the development of innovative technologies and solutions to address human health problems.

"It will foster the development of new technology and IT solutions for human health problems," said Professor Rosenfeld.

"University-industry collaboration is an important goal to create new opportunities for Australian innovation to reach the marketplace."

PROMOTED CONTENT

Brewer added, “Health is a key area for Leidos globally and as we continue to grow domestically, we will be looking to further develop our range of capabilities in this area."

The MoU will also see Leidos Australia and the MIME collaborate on future R&D with the initial contribution including the funding of a PhD research student.

Leidos is one of the primes tendering for Defence's Deployable Health Capability (JP2060 Phase 3), which aims to introduce an entire system (mission system), inclusive of all medical and dental equipment (a turn key solution) and designed to operate as an integrated capability.

The company also signed another MoU with the University of New South Wales to collaborate on research into the development of force protection and biological security for the Australian Defence Force.

JP2060 Phase 3 contender sets sights on human health research
Monash-Leidos-MoU.jpg
lawyersweekly logo

 

more from defence connect

Sep 25 2020
Consumer calls for ‘ethical manufacturing’ perfect to shift policy dialogue
Growing concerns about global exploitation of cheap labour have seen an increasing number of busines...
Jack Kormas
Sep 24 2020
PODCAST: LAND 129 Phase 3 and supporting sovereign UAS capabilities – Jack Kormas, managing director, Textron Systems Australia
While much of the focus for sovereign industrial capabilities has been for Defence’s big-ticket it...
Raytheon Australia announces team of Aussie SMEs for LAND 129 bid
Sep 24 2020
Raytheon Australia announces team of Aussie SMEs for LAND 129 bid
Raytheon Australia has announced its team of 10 Australian SMEs to deliver a fully sovereign Austra...
FROM THE WEB
Recommended by Spike Native Network